Ocular Inflammation

3

Review clinical trials related to Ocular Inflammation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Ear Nerve Stimulation to Treat Eye Inflammation

The purpose of this study to find out whether a device that delivers mild electrical stimulation to the ear (transcutaneous auricular vagus nerve stimulation, or taVNS) can reduce inflammation in the eye in people with ocular inflammatory conditions. The device is called the Cymbathera One System.

Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Sep 21, 2026Locations: 7
Eligibility criteria

Age ≥18 years [+5]

Evidence of active infection [+19]

Status: Recruiting

Dextenza in the Post-op Management of Vitreoretinal Surgeries

This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group. Patients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.

Participants needed: 30
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: The Cleveland ClinicUpdated: Jul 29, 2026Locations: 1
Eligibility criteria

Men and women >18 years old [+1]

Patients undergoing combined cataract or glaucoma procedure, intraocular lens ex... [+16]

Status: Recruiting

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

We propose to evaluate the efficacy of treatment with Hydrocortisone and Dexamethasone (in a cross-over design) in patients with ocular prostheses and significant functional discomfort.

Participants needed: 30
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: AgnesUpdated: Aug 15, 2025Locations: 1
Eligibility criteria

Patient aged 18 years or older; [+5]

Treatment with eye drop(s) (other than artificial tears or antiseptic) < 1 month... [+10]